Pipeline & Platform

Pearl Therapeutics (Pearl) is developing fixed-dose combination product candidates for the treatment of prevalent chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma and rhinosinusitis.

Each of these product candidates incorporates approved drug actives, off-the-shelf Metered Dose Inhaler (MDI) components, conventional manufacturing processes, and Pearl’s innovative proprietary particle platform. Bevespi Aerosphere was launched in the US during the first quarter 2017 and has regulatory submission acceptance in EU for COPD. To learn more about our platform technology, please click here.

Bevespi Aerosphere (PT003)

Bevespi Aerosphere, Pearl’s lead combination medicine, which was recently launched in the US, is composed of glycopyrronium, a long-acting muscarinic antagonist (LAMA), and formoterol fumarate, a long acting beta-2 agonist (LABA), administered twice daily, using an inhalation aerosol that uses patented, proprietary Co-suspension Delivery Technology. Bevespi Aerosphere is the only approved LAMA/LABA combination product in a pressurised MDI dosage formulation.

PT001 / PT005

PT001 and PT005 are Pearl's monotherapy Co-Suspension Delivery Technology potential new medicines. PT001 contains the LAMA and PT005 contains the LABA. Glycopyrronium and formoterol fumarate (GFF) are highly potent bronchodilators under evaluation to treat patients with chronic obstructive pulmonary disease (COPD). By leveraging the flexibility of the Co-Suspension Delivery Technology platform, the Company has been able to evaluate doses of these monotherapy products as low as 600 nanograms in patients with COPD.

PT010

PT010 is a triple combination of GFF and budesonide, an inhaled corticosteroid (ICS). As with Pearl’s monotherapy and dual combination Co-Suspension delivery technology product potential new medicines, PT010 is delivered using a standard MDI.

PT008 / PT009

PT008 is a monotherapy that uses the Co-Suspension Delivery Technology, containing ICS. PT009 is the dual combination of the LABA and ICS. By leveraging the flexibility of Pearl’s Co-Suspension Delivery Technology platform, the Company has also been able to formulate the mono and dual combination potential new medicines, as well as PT010 triple combination with virtually no co-formulation effects.

Pipeline

PT003

Glycopyrronium and formoterol (GFF MDI)

PT001

Glycopyrronium (GP MDI)

PT010

Budesonide, glycopyrronium and formoterol (BGF MDI)

PT008

Budesonide (BUD MDI)

PT009

Budesonide and formoterol (BFF MDI)